全聘课题组长
首页  人才队伍  全聘课题组长
  • 柳素玲

    博士,研究员,博士生导师
    地址:东安路 270号,复旦大学附属肿瘤医院2号楼1317B室,上海 200032
    电话:021-34771023(办公室),021-34774409 (实验室)
    邮箱:suling@fudan.edu.cn

工作经历
研究员,复旦大学,生物医学研究院/附属肿瘤医院(2016.12-今)
教授,中国科学技术大学,生命科学学院(2012.11-2016.11)
研究助理教授,美国密西根大学(2010.10-2012.10)
助理研究员,美国密西根大学(2006.10-2010.09)
博士后,美国密西根大学(2003.12-2006.09)
教育经历
博士,美国俄亥俄州立大学,生物学系(1997-2003)
学士,中国科学技术大学,生物系(1992-1997)
所获人才项目

 国家万人计划,中组部,2021
 上海市领军人才, 上海市委和上海人社局, 2021
 科技部中青年科技创新领军人才, 科技部, 2020
 复旦大学“卓越2025”: 卓识杰出人才, 复旦大学,2020
 上海市医学领军人才,上海市卫健委,2019
 国家优秀青年科学基金,国家自然科学基金,2014

所获奖项

药明康德生命化学研究奖,2020
中国肿瘤青年科学家奖,中国抗癌协会,2018
中美抗癌协会-美国国家癌症基金学术奖,中美抗癌协会,2014
Susan G. Komen Scholar in Training Award,美国癌症协会,2010
Merck Scholar in Training Award,美国癌症协会,2006

研究方向
1)乳腺肿瘤干细胞的异质性及其调控和耐药研究;
2)乳腺肿瘤干细胞的起源研究;
3)肿瘤微环境与肿瘤干细胞的互作研究;
4)肿瘤干细胞的免疫调控研究;
5)靶向肿瘤干细胞的新型治疗策略研究及药物开发。
代表论文
  1. Xu, J., Yang, X., Deng, Q., Yang, C., Wang, D., Jiang, G., Yao, X., He, X., Ding, J., Qiang, J., Tu, J., zhang, R., Lei, Q.-Y., Shao, Z.-m., Bian, X.*, Hu, R.*, Zhang, L.*, and Liu, S.* (2021) TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer. Nature Communications 12, 4413*为通讯作者或共同通讯作者

  2. Zhang, R.#, Tu, J.#, Liu, S.*.  Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity. Seminars in Cancer Biology, 2021. PMID: 33737107(*为通讯作者)

  3. Huang, Y.#, Wang, H., Hao, Y., Lin, H., Dong, M., Ye, J., Song, L., Wang, Y., Li, Q., Shan, B., Jiang, Y., Li, H., Shao, Z.M., Kroemer, G., Zhang, H., Bai, L., Jin, T., Wang, C., Ma, Y., Cai, Y., Ding, C., Liu, S.*,Pan, Y.*, Jiang, W.*, Zhou R.*. Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity. Nature Cell Biology , 2020.(*为通讯作者或共同通讯作者)

  4. Zhang, F. #, Liu, B., Deng, Q., Sheng, D., Xu, J., He, X., Zhang, L.*, Liu, S.*. UCP1 regulates ALDH-positive breast cancer stem cells through releasing the suppression of Snail on FBP1. Cell Biol Toxicol (online), 2020. PMID:32472219(*为通讯作者)

  5. Zhang, F. #, Liu, S.*. Mechanistic insights of adipocyte metabolism in regulating breast cancer progression. Pharmacological Research 6(155):104741, 2020. PMID:32151679(*为通讯作者)

  6. Qin, Y. #, Chen, W. #, Jiang, G., Zhou, L., Yang, X., Li, H., He, X., Wang, H., Zhou, Y., Huang, S., Liu,S.*. Interfering MSN-NONO complex activated CREB signaling serves a novel therapeutic strategy for triple-negative breast cancer, Science Advances 6(8), 2020.PMID: 32128390.

  7. Zhang, L. #, Qiang, J. #, Yang, L. #, Wang, D., Adeel, R., He, X., Chen, W., Sheng , D., Zhou, L., Jiang, Y. Z., Li, T., Du, Y., Feng, J., Hu, X., Zhang, J., Hu, X. C., Shao, Z. M., Liu, S.*. IL1R2 blockade suppresses breast tumorigenesis and progression by impairing USP15-dependent BMI1 stability. Advanced Science 7(1):1901728, 2020. PMID: 31921558

  8. Zhou L. #, Wang, D. #, Sheng, D. #, Xu, J., Chen, W., Qin, Y., Du, R., Yang, X., He, X., Xie, N.*, Liu, S.*, Zhang, L.*. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer. Theranostics 10(5): 2405-2421, 2020.PMID:32104513

  9. Zhang, J., Yang, Y., Zhou, S., He, X., Cao, X., Wu, C., Hu, H., Qin, J., Wei, G., Wang, H., Liu, S.*, Sun, L.*. Membrane-bound TNF mediates microtubule-targeting chemotherapeutics-induced cancer cytolysis via juxtacrine inter-cancer-cell death signaling.Cell Death and Differentiation485, 2019. PMID: 31645676

  10. Jiang, G.#, Wang, X.#, Sheng, D., Zhou, L., Liu, Y., Xu, C., Liu, S.* and Zhang, J.*. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function. Theranostics 9(22): 6501-6516, 2019. PMID: 31588232

  11. Jin, X. #, Xu, X-E. # *, Jiang, Y-Z. #, Liu, Y-R., Sun, W., Guo, Y-J., Ren, Y-X., Zuo, W-J., Hu, X., Huang, S-L., Shen, H-J., Lan, F., He, Y-F., Hu, G-H., Di, G-H., He, X-H., Li, D-Q., Liu, S.*, Yu, K-D.*,, Shao, Z-M.*. The endogenous retrovirus-derived long noncodingRNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation. Science Advances 5(3): eaat9820, 2019. PMID: 30854423

  12. Liu, J., Duan, Z., Guo, W., Zeng, L., Wu, Y., Chen, Y., Tai, F., Wang, Y., Lin, Y., Zhang, Q., He, Y., Deng J., Stewart, R., Wang, C., Lin, P., Ghaffari, S., Evers, B.M., Liu, S.*, Zhou, M-M.*, Zhou, B.*, and Shi, J.*. Targeting the BRD4/FOXO3a/CDK6 axis Sensitizes AKT Inhibition in Luminal Breast Cancer. Nature Communications 9(1): 5200, 2018. PMID: 30518851

  13. Liu, B., Du, R., Zhou L., Xu, J., Chen, S., Chen, J., Yang, X., Liu, D-X., Shao, Z-M., Zhang, L., Yu, Z., Xie, N. *, Guan, J-L.*, and Liu, S.*. miR-200c/141 regulates breast cancer stem cell heterogeneity via targeting HIPK1/β-catenin axis. Theranostics 8(21):5801-5813, 2018. PMID: 30613263

  14. Deng, L., Gao, X., Liu, B., He, X., Xu, J., Qiang, J., Wu, Q., Liu, S.*. NMT1 inhibition modulates breast cancer progression through stress-triggered JNK pathway. Cell Death and Disease 9(12):1143, 2018. PMID: 30446635

  15. Chen, W., Qin, Y., Wang, D., Zhou, L., Liu, Y., Chen, S., Yin, L., Xiao, Y., Yao, X-H., Yang, X., Ma, W., Chen, W., He, X., Zhang, L., Yang, Q., Bian, X., Shao, Z-M., Liu, S.*CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. Plos Biology 16(7): e2005869, 2018. PMID: 30052635

  16. Liu, M., Liu, Y., Deng, L., Wang, D., He, X., Zhou, L., Wicha, M.S., Bai, F.*, Liu, S.*.Transcriptionalprofiles of differentstates of cancerstem cells in triple-negative breast cancer.Mol Cancer17(1): 65, 2018. PMID: 29471829

  17. Du, R., Liu, B., Zhou, L., Wang, D., He, X., Xu, X., Zhang, L., Niu, C.*, Liu, S.*. Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer.Cell Death and Disease9(2):126, 2018. PMID: 29374148

  18. Wang, D., Xu, J., Liu, B., He, X., Zhou, L., Hu, X., Qiao, F., Zhang, A., Xu, X., Zhang, H., Wicha, MS., Zhang, L., Shao, Z., Liu, S.*. IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing breast cancer. Cell Death and Differentiation25(2):330-339, 2018. PMID: 29027990

  19. Qin, Y., Chen, W., Liu, B., Zhou, L., Deng, L., Niu, W., Bao, D., Cheng, C., Li, D., Liu, S.*, Niu, C.*. MiR-200c Inhibits the Tumor Progression of Glioma via Targeting Moesin.Theranostics7(6):1663-1673, 2017.

  20. Liu, Y., Burness, M.L.*, Martin-Trevino, R., Guy, J., Bai, S., Harouaka, R., Brooks, M.D., Shang, L., Fox, A., Luther, T.K., Davis, A., Baker, T.L., Colacino, J., Clouthier, S.G., Shao, Z-M., Wicha, M.S., and Liu, S*. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer. Clinical Cancer Research 23(2): 514-522, 2017.

  21. Liu, S.*, Cong, Y., Wang, D., Sun, Y., Deng, L., Liu, Y., Martin-Trevino, R., Shang, L., McDermott, S. P., Landis, M. D., Hong, S., Adams, A., D'Angelo, R., Ginestier, C., Charafe-Jauffret, E., Clouthier, S. G., Birnbaum, D., Wong, S. T., Zhan, M., Chang, J.C.*, and Wicha, M.S.* Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts. Stem Cell Reports 2, 78-91,2014. PMID:24511467.

  22. Deng, L., Shang, L., Bai, S., Chen, J., He, X., Martin-Trevino, R., Chen, S., Li, X.-Y., Meng, X., Yu, B., Wang, X., Liu, Y., McDermott, S. P., Ariazi, A. E., Ginestier, C., Ibarra, I., Ke, J., Luther, T., Clouthier, S. G., Xu, L., Shan, G., Song, E., Yao, H., Hannon, G. J., Weiss, S. J., Wicha, M. S., and Liu, S*. MicroRNA100 Inhibits Self-Renewal of Breast Cancer Stem-like Cells and Breast Tumor Development. Cancer research74, 6648-6660, 2014. PMID:25217527.


Top